Oncolytic immunotherapies

Search documents
REPL Class Action Reminder: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Replimune Group, Inc. Class Action Lawsuit
Prnewswire· 2025-08-29 00:20
Group 1 - A class action has been filed on behalf of investors who purchased Replimune Group, Inc. (NASDAQ: REPL) securities between November 22, 2024, and July 21, 2025 [1] - Robbins LLP is investigating allegations that Replimune Group, Inc. misled investors regarding the viability of its IGNYTE trial, claiming that the company overstated the trial's prospects and failed to disclose material issues [2] - On July 22, 2025, Replimune announced it received a complete response letter (CRL) from the FDA, indicating that the IGNYTE trial was not considered adequate, leading to a significant stock price drop of $9.52 per share, or 77.24%, closing at $2.80 per share [3] Group 2 - Shareholders interested in participating as lead plaintiffs must file their papers with the court by September 22, 2025, and can remain absent class members if they choose not to participate [4] - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [5] - The firm has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5]
REPL Stock News: Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Replimune Group, Inc. Class Action Lawsuit
Prnewswire· 2025-08-12 22:51
Group 1 - A class action has been filed on behalf of investors who purchased Replimune Group, Inc. (NASDAQ: REPL) securities between November 22, 2024, and July 21, 2025 [1] - Robbins LLP is investigating allegations that Replimune Group, Inc. misled investors regarding the viability of its IGNYTE trial, claiming that the company overstated the trial's prospects and failed to disclose material issues [2] - On July 22, 2025, Replimune announced it received a complete response letter (CRL) from the FDA, indicating that the IGNYTE trial was not considered adequate and well-controlled, leading to a significant stock price drop of $9.52 per share, or 77.24%, closing at $2.80 per share [3] Group 2 - Shareholders interested in serving as lead plaintiff must file their papers with the court by September 22, 2025, and can remain absent class members if they choose not to participate [4] - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [5] - The firm has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5]
REPL Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Securities Fraud Class Action Involving Replimune Group, Inc.
Prnewswire· 2025-07-30 10:10
Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Replimune Group, Inc. (NASDAQ: REPL) securities during the specified period, alleging that the company misled investors regarding the viability of its IGNYTE trial [1][2]. Group 1: Allegations and Legal Proceedings - The lawsuit claims that Replimune Group, Inc. failed to disclose significant issues regarding the IGNYTE trial, which led to the FDA deeming the trial inadequate and not well-controlled [2]. - It is alleged that the defendants overstated the prospects of the IGNYTE trial, resulting in materially false and misleading statements about Replimune's business and operations [2]. - Following the announcement of a complete response letter (CRL) from the FDA on July 22, 2025, which indicated that the IGNYTE trial did not provide substantial evidence of effectiveness, Replimune's stock price fell by $9.52 per share, or 77.24%, closing at $2.80 per share [3]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by September 22, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 3: Company Background - Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing and commercializing oncolytic immunotherapies for cancer treatment [1]. - Robbins LLP has been recognized for its efforts in shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance since 2002 [5].
REPL Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against Replimune Group, Inc.
GlobeNewswire News Room· 2025-07-28 12:10
Core Viewpoint - A class action lawsuit has been filed against Replimune Group, Inc. for allegedly misleading investors regarding the viability of its IGNYTE trial, which has resulted in significant stock price decline following a complete response letter from the FDA [1][2][3]. Allegations - The lawsuit claims that Replimune's management overstated the prospects of the IGNYTE trial, which the FDA deemed inadequate and not well-controlled [2]. - Defendants are accused of making materially false and misleading statements about the company's business and operations throughout the class period [2]. Stock Impact - Following the announcement of the complete response letter from the FDA on July 22, 2025, Replimune's stock price fell by $9.52 per share, representing a 77.24% decrease, closing at $2.80 per share [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs must file their papers by September 22, 2025, but they can also remain absent class members without taking action [4].